Mode
Text Size
Log in / Sign up
N/A N=16 Randomized Double-blind Treatment

Effects of a Walking Program and Inspiratory Muscle Training in Individuals With Chronic Heart Failure

Heart Failure NYHA Class II · Heart Failure NYHA Class III

Enrolled (actual)
16
Serious AEs
18.8%
Results posted
Apr 2020
Primary outcome: Primary: Change From Baseline in Mean Minnesota Living With Heart Failure Questionnaire Score — 36; 57.6; 18.6; -20.6 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
High-intensity IMT plus walking (Behavioral); Low-intensity IMT plus walking (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Texas Woman's University
Primary completion
Jan 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Mean Minnesota Living With Heart Failure Questionnaire Score
36; 57.6; 18.6; -20.6
PRIMARY
Change From Baseline in Mean Score of Physical Component of the SF-36 Questionnaire
34.1; 30.7; 0.82; 7.08
SECONDARY
Mean Daily Step Counts From Week 1 to Week 6
3512; 7002; 4434; 9255
SECONDARY
Respiratory Muscle Strength is Indicated by Maximal Inspiratory Pressure (PImax)
51.44; 43.53; 57.22; 58.13
SECONDARY
Six-minute Walk Test Distance
356.16; 378.04; 375.78; 419.71

Summary

Individuals with chronic heart failure need a "safe and effective" exercise program that could enhance their quality of life. In this study, we examined whether an experimental exercise program of autonomous walking and high-intensity Inspiratory Muscle Training (IMT) could result in better effects on respiratory muscle strength (PImax), cardiovascular endurance, quality of life, and physical activity, when compared to autonomous walking and "sham" IMT program, in adults with chronic heart failure.

Eligibility Criteria

Inclusion Criteria

  • adults with chronic heart failure (NYHA Functional Class II-III)
  • BMI < 35 kg/m^2
  • Age: 18 to 90 years
  • walk independently with or without an assisted device
  • hospital discharge for CHF within a year.

Exclusion Criteria

  • ECG with uncontrolled ventricular arrhythmia
  • bronchiectasis
  • limited walking ability due to neurologic or orthopedic impairments of the legs
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01560871). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search